Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Atrium Innovations has entered into a definitive agreement to sell its Active Ingredients and Specialty Chemicals division to AXA Private Equity for $155 million in cash, subject to working capital adjustments.
Subscribe to our email newsletter
Total proceeds from the sale, including excess cash in the business, are expected to be $165 million, subject to working capital adjustments. The completion of the transaction is subject to certain customary conditions, including receipt of a limited number of regulatory approvals, but is not subject to any financing condition.
The parties expect the transaction to be completed by mid May, 2008. Following the transaction, the main office of the Active Ingredients and Specialty Chemicals division will remain in Quebec City under the leadership of Charles Boulanger, president of the Active Ingredients and Specialty Chemicals division, and its existing management team.
Pierre Fitzgibbon, president and CEO of Atrium, said: “This transaction will allow us to optimize the creation of shareholder value by focusing exclusively on the Health and Nutrition industry, where we intend to continue to play the role of a strategic consolidator in a conducive industry environment.”